Observatory · observe first

Follow the allocation change

Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.

Historical time machine

Historical observation

20182026

Universe›Health Care›Biotechnology›Biotechnology

1 · Sector

Weight and 12M allocation change

Information Technology17.4%+1.34 pp Energy5.1%+0.43 pp Real Estate3.5%+0.28 pp Utilities3.4%+0.26 pp Health Care16.9%+0.12 pp Consumer Discretionary7.0%-0.03 pp Materials2.1%-0.04 pp Communication Services3.3%-0.15 pp Consumer Staples8.8%-0.60 pp Financials17.7%-0.75 pp Industrials14.7%-0.86 pp

2 · Industry

Inside Health Care

Health Care Equipment3.10%+0.28 pp Biotechnology3.11%-0.27 pp Managed Health Care2.11%+0.16 pp Health Care Distributors0.42%-0.09 pp Health Care Services0.66%-0.05 pp Health Care Supplies0.18%+0.05 pp Life Sciences Tools & Services1.55%+0.03 pp Health Care Facilities0.22%+0.01 pp Pharmaceuticals5.50%+0.00 pp Health Care Technology0.00%+0.00 pp

3 · Sub-industry

Inside Biotechnology

Biotechnology3.11%-0.273 pp

Concentrated

Most of this industry's losses came from a few companies.

View all contributions →

Biotechnology · weight

3.11%

Industry change · 12M

-0.27 pp

Biotechnology · contribution

-0.273 pp

Company participation

29%

of industry constituents above their 6M weight average

4 · Companies driving this sub-industry

Jun 2018 · sorted by absolute contribution to 12-month change

Company	Country	Market cap	Universe weight	3M contribution	12M contribution	12M price return	Above 6M weight average
AbbVie → ABBV	United States	$147.0bn	0.892%	-0.030 pp	-0.130 pp	-16.6%	No
Gilead Sciences → GILD	United States	$92.1bn	0.559%	-0.047 pp	-0.066 pp	-14.2%	No
Biogen → BIIB	United States	$61.2bn	0.372%	+0.016 pp	-0.048 pp	-16.6%	No
Amgen → AMGN	United States	$122.1bn	0.741%	-0.013 pp	-0.029 pp	+0.7%	No
Incyte → INCY	United States	$14.2bn	0.086%	-0.022 pp	-0.023 pp	-25.8%	No
Vertex Pharmaceuticals → VRTX	United States	$43.3bn	0.263%	+0.009 pp	+0.022 pp	+1.9%	Yes
Regeneron Pharmaceuticals → REGN	United States	$32.4bn	0.197%	-0.002 pp	+0.000 pp	-5.9%	Yes

Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.